Successful factor XIII administration for persistent chylothorax after lung transplantation for lymphangioleiomyomatosis.
Lung transplantation has emerged as a viable treatment option for patients with end-stage lymphangioleiomyomatosis (LAM), and therapeutic outcome results reported thus far have been satisfactory. However, persisting chylothorax after transplantation for LAM remains a challenging problem, and the optimal management has not been decided. We present the case with persistent chylothorax after lung transplantation for LAM, in which the intravenous administration of a tissue repair factor (human factor XIII) resulted in complete resolution of chylous effusion without performing additional invasive treatments, leading to a successful transplant outcome.
Shigemura
Norihisa
N
Department of General Thoracic Surgery, Osaka University Graduate, School of Medicine, Osaka, Japan. shigemura@thoracic.med.osaka-u.ac.jp
Kawamura
Tomohiro
T
Minami
Masato
M
Sawabata
Noriyoshi
N
Inoue
Masayoshi
M
Utsumi
Tomoki
T
Nakagiri
Tomoyuki
T
Matsumiya
Goro
G
Sawa
Yoshiki
Y
Okumura
Meinoshin
M
D000328:Adult; D015505:Chest Tubes; D002916:Chylothorax / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008171:Lung Diseases / Q000000981:diagnostic imaging / Q000601:surgery*; D016040:Lung Transplantation; D018192:Lymphangioleiomyomatosis / Q000000981:diagnostic imaging / Q000601:surgery*; D018700:Pleurodesis; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D013907:Thoracostomy
D005341:Fibrinolysin